BMO Capital Markets Cuts Biogen (NASDAQ:BIIB) Price Target to $139.00
Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by BMO Capital Markets from $156.00 to $139.00 in a report released on Thursday morning,Benzinga reports. BMO Capital Markets currently has a market perform rating on the biotechnology company’s stock. BIIB has been the topic of a number of other reports. Royal Bank of Canada […]
Biogen (NASDAQ:BIIB – Free Report) had its price target decreased by BMO Capital Markets from $156.00 to $139.00 in a report released on Thursday morning,Benzinga reports. BMO Capital Markets currently has a market perform rating on the biotechnology company’s stock. BIIB has been the topic of a number of other reports. Royal Bank of Canada […]
